Supporting Information

Asymmetric Synthesis of Actinoidic Acid Derivatives

Sabine Boisnard, Luc Neuville, Michèle Bois-Choussy, Jieping Zhu*

Institut de Chimie des Substances Naturelles, CNRS, 91198 Gif-sur-Yvette, France

zhu@icsn.cnrs-gif.fr



In a two-neck round-bottom flask equipped with a water condenser and a dropping funnel, was placed magnesium (155.0 mg, 6.32 mmol) and flame dried,. A solution of oxazoline **6** (642.0 mg, 2.05 mmol) in anhydrous THF (3 mL) was then introduced and the mixture was heated to 80-90°C. Dibromoethane (455.0 μ L, 5.30 mmol) dissolved in anhydrous THF (5 mL) was slowly added via a dropping funnel over 50 min. The reaction mixture was heated to reflux for an additional 30 min before a solution of oxazoline **5** (419 mg, 1.58 mmol) in anhydrous THF (3 mL) was added. After being refluxed for 15 h, the reaction mixture was quenched with aqueous saturated NH₄Cl. The aqueous phase was extracted with ether, then CH₂Cl₂. The combined organic phases were washed with brine, dried over Na₂SO₄, concentrated and the resulting yellow oil was purified by flash chromatography (2/1 Hep/ether, SiO₂) to give **11** (640.6 mg; 87%) as a yellow crystalline solid: [α]_D = + 36.5 (*c* 1.0, CHCl₃); IR (CHCl₃) v 3697, 2973, 1658, 1602, 1461, 1363, 1270 cm⁻¹: ¹H NMR (CDCl₂ 300 MHz 2 atropisomers in one to one ratio) δ 1 18 (s 3H) 1 19 (s 3H)

1.27 (s, 9H), 3.58 (d, J = 1 Hz, 1H), 3.60 (d, J = 1 Hz, 1H), 3.68, 3.69 (s, 3H), 3.72 (s, 3H), 3.86 (s, 3H), 4.03, 4.06 (dd, J = 7.8, 8.0 Hz, 1H), 4.51, 4.55 (dd, J = 2.0, 8.3 Hz, 1H), 5.10 (m, 1H), 6.60 (d, J = 2.4 Hz, 1H), 6.86, 6.87 (d, J = 7.7 Hz, 1H), 6.86, 6.88 (d, J = 2.4 Hz, 1H), 6.91, 6.92 (d, J = 2.3 Hz, 1H), 7.13, 7.16 (dd, J = 2.3, 7.7 Hz, 1H); ¹³C NMR (CDCl₃, 75 MHz, 2 atropisomers in one to one ratio) δ 28.0/ 28.1, 29.7, 33.4, 55.5, 55.9, 56.0, 67.1, 68.7/69.2, 74.9/75.1, 79.3/79.4, 101.4, 104.8/104.9, 110.6/110.9, 120.5, 126.1/126.5, 126.3, 129.4/129.8, 130.8, 134.2/134.3, 156.9/157.1, 158.3, 159.7, 163.4/163.6, 174.7; MS (CI) *m/z* 467 [M+H]⁺; Anal. Calcd. for C₂₇H₃₄N₂O₅: C, 69.50; H 7.34; N 6.00. Found: C, 69.05; H, 7.64; N 5.94.



To a solution of **11** (666.0 mg, 1.43 mmol) in anhydrous methanol (2.3 mL) was added TFA (438 µL, 5.72 mmol, 4 eq) dropwise via a syringe. The mixture was stirred at room temperature, under an argon atmosphere for 2 h and was concentrated in vacuo to give crude amino ester 12 which was directly engaged in the following reaction. To the solution of the so obtained crude amino ester in dioxane and saturated aqueous NaHCO3 was added CbZOSu (712 mg, 2.86 mmol, 2 eq). After being stirred at room temperature for 2 h, the reaction mixture was diluted with saturated aqueous NH₄Cl and extracted with EtOAc. The organic phase was washed with brine, dried over Na₂SO₄, concentrated and the resulting solid was purified by flash chromatography (2/3 EtOAc/Hep, SiO₂) to afford 13 as a white crystalline solid (680 mg; 77%): Rf = 0.29 (3/2) EtOAc/Hep); m.p. 54°C; [α]_D -20.0 (c +7.5, CHCl₃); IR (CHCl₃) v 3440, 2971, 1724, 1601, 1505, 1463, 1266 cm⁻¹; ¹H NMR (250 MHz, CDCl₃, 2 atropisomers in one to one ratio) δ 7.33 (s, 5H), 7.22 (dd, J = 8.5, 1.8 Hz, 1H), 7.05 (d, J = 1.8 Hz, 1H), 6.90 (d, J = 2.2 Hz, 1H), 6.84 (d, J = 8.5 Hz, 1H), 6.61 (d, J = 2.2 Hz, 1H), 5.23 (d, J = 7.8 Hz, 1H), 5.01-5.15 (m, 3H), 4.19-4.33 (m, 2H), 3.87 (s, 3H), 3.73 (s, 3H), 3.69 (s, 3H), 3.59 (d, J = 8.0 Hz, 1H), 3.53 (d, J = 8.0Hz, 1H), 1.16 (s, 15H); ¹³C NMR (75 MHz, CDCl₃, 2 atropisomers in one to one ratio) δ 178.5, 163.3, 159.8, 158.3, 157.4, 155.8, 136.5, 130.8, 129.8, 129.7, 129.6, 128.6, 128.2, 127.0, 126.6, 120.2, 110.8, 110.8, 101.5, 101.4, 67.2, 66.9, 66.7, 66.5, 56.0, 55.7, 53.9, 38.9, 31.0, 28.1, 28.0, 27.2; MS (CI): m/z 618; Anal. Calcd for C₃₅H₄₂N₂O₈: C, 67.94; H, 6.84; N, 4.52.



To a solution of 13 (743 mg, 1.20 mmol) in acetone (10 mL) was added MeI (226 µL, 3.60 mmol, 3 eq). The mixture was stirred at 40°C under an argon atmosphere for 15 h until the disappearance of the starting material. The mixture was concentrated in vacuo to give a yellow crystalline solid, which was filtered, washed with pentane, then dried in vacuo. To the solution of the so obtained oxazolinium salt in anhydrous CH₂Cl₂ was added, at 0°C, L-Selectride® (2.40 mL, 1 M in hexane, 2.40 mmol, 2 eq). The mixture was stirred at 0° C, under an argon atmosphere for 5 min, then a saturated aqueous solution of citric acid and a small amount of silica gel were added. The reaction mixture was vigourosly stirred for 5 h at 0°C and was brought back to room temperature. The mixture was extracted with CH_2Cl_2 . The combined organic extracts were dried over Na₂SO₄ and concentrated. Flash chromatography (3/2 Hep/EtOAc, SiO₂) afforded 14 as a pinkish crystalline solid (594 mg, 90%): Rf = 0.37 (2/3 EtOAc/Hep); m.p. 50°C; $[\alpha]_D$ -3.7 (c 1.4, CHCl₃); IR (CHCl₃) v 3025, 1718, 1681, 1606, 1512, 1475, 1340 cm⁻¹; ¹H NMR (250 MHz, CDCl₃ 2 atropisomers in one to one ratio) δ 9.58 (s, 1H), 7.28-7.38 (m, 6H), 7.17 (dd, J = 2.9, 2.9 Hz, 1H), 7.11 (d, J = 2.2 Hz, 1H), 6.95 (d, J = 8.5 Hz, 1H), 6.77 (d, J = 2.2 Hz, 1H), 5.28 (br s, 1H), 5.00-5.15 (m, 1H), 5.14 (d, J = 12.2 Hz, 1H), 5.07 (d, J = 12.2 Hz, 1H), 4.34 (dd, J = 5.2, 11.5 Hz, 1H), 4.27 (dd, J = 6.5, 11.5 Hz, 1H), 3.90 (s, 3H), 3.72 (s, 3H), 3.70 (s, 3H), 1.16 (s, 9H); ¹³C NMR (75 MHz, CDCl₃, 2 atropisomers in one to one ratio) δ 192.3, 178.5, 160.3, 158.4, 157.1, 155.8, 136.3, 135.7, 131.1, 130.3, 128.6, 128.2, 127.8, 124.2, 122.3, 110.9, 105.1, 100.6, 67.0, 66.2, 53.0, 55.7, 55.7, 38.9, 29.8, 27.1; MS (CI): m/z 550.



A solution of sulfinamide 15^1 (217 mg, 1.39 mmol, 1.5 eq), aldehyde 14 (512 mg, 0.93 mmol, 1 eq), titanium (IV) ethoxide (975 µL, 4.65 mmol, 5 eq) in anhydrous CH₂Cl₂ (50 mL),was refluxed for 4 h under an argon atmosphere. The reaction mixture was cooled down to 0°C and

quenched by addition of H₂O. The turbid solution was filtered through celite and the filter cake was washed with CH_2Cl_2 . The phases were separated, the aqueous phase was extracted with CH_2Cl_2 and the combined organic portions were washed by brine, dried over Na₂SO₄ and concentrated in vacuo. The resulting crude product was purified by flash chromatography (2/1 Hep/EtOAc, SiO₂) to afford 16 (white solid, 416 mg; 65%) as a non separable mixture of 2 atropisomers: Rf = 0.42 (3/2 Hep/EtOAc); m.p. 58°C; [a]_D+88.0 (c 2.0, CHCl₃); IR (CHCl₃) v 3690, 3442, 3022, 3015, 2400, 1724, 1608, 1505, 1479, 1399, 1323, 1288, 1265, 1573 cm⁻¹; ¹H NMR (250 MHz, CDCl₃, 2 atropisomers in one to one ratio) δ 8.40, 8.38 (s, 1H), 7.57 (d, J = 6.5 Hz, 1H), 7.53 (d, J = 6.5Hz, 1H), 7.31 (m, 1H), 7.30 (br s, 5H), 7.25, 7.21 (d, J = 2.5 Hz, 1H), 7.12, 7.06 (d, J = 2.3Hz, 1H), 6.95 (d, J = 8.6 Hz, 1H), 6.66, 6.67 (d, J = 2.5 Hz, 1H), 5.25 (br s, 1H), 5.06-5.17 (m, 3H), 4.32 (dd, J = 11.3, 5.7 Hz, 1H), 4.28 (dd, J = 11.3, 4.9 Hz, 1H), 3.87, 3.86 (s, 3H), 3.72, 3.69 (s, 3H), 3.68, 3.60 (s, 3H), 2.49, 2.48 (s, 3H), 1.16 (s, 9H); ¹³C NMR (75 MHz, CDCl₃ 2 atropisomers in one to one ratio) & 178.5, 160.6, 160.4, 160.0, 158.3, 157.0, 155.8, 148.0, 142.0, 136.3, 133.8, 131.2, 130.2, 129.8, 129.7, 128.5, 128.1, 127.9, 125.0, 124.8, 111.36, 103.3, 103.2, 102.0, 101.9, 66.9, 66.1, 55.9, 55.7, 55.6, 53.8, 38.8, 27.1, 21.44; . MS (CI): *m/z* 547; Anal. Calcd for C₃₈H₄₂N₂O₈S: C, 66.45; H, 6.16; N, 4.07. Found: C, 66.74; H, 6.31; N, 4.01.



In a round-bottom flask was dissolved the sulfinimine **16** (56.0 mg, 0.08 mmol) in anhydrous THF (3.0 mL) and cooled to -78° C. In a separate round-bottom flask were introduced THF (6.0 mL), Et₂AlCN (3.32 mL, 0.40 mmol, 5 eq) and anhydrous ^{*i*}PrOH (169 µL, 0.26 mmol, 3.3 eq). The solution was stirred for 15 min at room temperature, under an argon atmosphere and added via a syringe to the sulfinimine solution at -78° C. After 15 min, the reaction mixture was brought to room temperature, stirred overnight. The reaction mixture was recooled to -78° C and quenched by addition of aqueous NaHCO₃. The suspension was diluted with EtOAc, filtered trough celite. The filter cake was washed with EtOAc. The filtrate was diluted with H₂O and extracted with EtOAc. The combined organic layers were dried over Na₂SO₄, concentrated to give the crude product which was purified by flash chromatography (3/2 Hep/EtOAc, SiO₂) to give 2 separable atropisomeres **17** and **18**, as 2 white solids (1/1, 53 mg, 91% yield). Compound **17**: Rf = 0.20 (3/2 Hep/EtOAc); m.p. 66^{\circ}C; [\alpha]_D +47.5 (*c* 1.5, CHCl₃); IR (CHCl₃) v 3440, 3343, 3022, 3015,

2960, 2840, 2401, 2349, 2245, 1720, 1606, 1508, 1490, 1463, 1223, 1160 cm⁻¹; ¹H NMR (250 MHz, CDCl₃) δ 7.39 (d, J = 8.1 Hz, 3H), 7.28 (br s, 5H), 7.18 (d, J = 1.9 Hz, 1H), 7.17 (d, J =8.1 Hz, 2H), 6.92 (d, J = 8.5 Hz, 1H), 6.74 (d, J = 2.2 Hz, 1H), 6.55 (d, J = 2.2 Hz, 1H), 6.44 $(d, J = 8.2 \text{ Hz}, 1\text{H}), 5.10 \text{ (m, 3H)}, 5.00 \text{ (d, } J = 4.0 \text{ Hz}, 1\text{H}), 4.64 \text{ (d, } J = 4.0 \text{ Hz}, 1\text{H}), 4.41 \text{ (dd, } J = 4.0 \text{ Hz}, 1\text{Hz}), 4.41 \text{ (dd, } J = 4.0 \text{ Hz}, 1\text{Hz}), 4.41 \text{ ($ J = 11.0, 6.7 Hz, 1H), 4.34 (dd, J = 11.0, 7.3 Hz, 1H), 3.88 (s, 3H), 3.68 (s, 3H), 3.66 (s, 3H), 2.38 (s, 3H), 1.10 (s, 9H); ¹³C NMR (62.5 MHz, CDCl₃) δ 178.4, 161.1, 158.8, 157.0, 156.2, 142.3, 138.9, 136.9, 134.5, 123.3-130.6, 118.2, 111.1, 103.5, 100.2, 67.1, 65.4, 56.0, 55.8, 55.7, 53.8, 42.2, 38.8, 27.1, 21.5; MS (FAB) m/z 720 [M+Li]⁺; Anal. Calcd for C₃₉H₄₃N₃O₈S: C, 65.62; H, 6.07; N, 5.88. Found: C, 65.02; H, 6.01; N, 5.78. Compound 18: Rf = 0.11 (3/2 Hep/EtOAc); m.p. 68°C; [a]_D +41.5 (c 2.8, CHCl₃); IR (CHCl₃) v 3682, 3440, 3030, 3013, 2961, 2935, 2399, 2361, 1716, 1606, 1507, 1490, 1463, 1420, 1339 cm⁻¹; ¹H NMR (250 MHz, CDCl₃) δ 7.51 (d, J = 7.9 Hz, 2H), 7.20-7.33 (m, 8H), 7.02 (d, J = 1.8 Hz, 1H), 6.99 (d, J = 8.0 Hz, 1H), 6.82 (d, J = 2.2 Hz, 1H), 6.56 (d, J = 2.2 Hz, 1H), 5.30 (br s, 1H), 5.11, (m, 4H), 4.66 (d, J = 2.3 Hz, 1H), 4.35 (m, 2H), 3.87 (s, 3H), 3.76 (s, 3H), 3.65 (s, 3H), 2.40 (s, 3H), 1.15 (s, 9H); ¹³C NMR (50 MHz, CDCl₃) & 178.5, 160.9, 158.8, 156.9, 155.9, 142.3, 139.7, 136.5, 134.4, 123.3-130.9, 119.4, 111.7, 104.1, 100.2, 67.0, 65.9, 56.0, 55.8, 55.7, 53.7, 41.5, 38.9, 27.2, 21.6; MS (FAB) m/z 720 [M+Li]+; Anal. Calcd for C₃₉H₄₃N₃O₈S: C, 65.62; H, 6.07; N, 5.88. Found: C, 65.52; H, 6.51; N, 5.92.



Compound **17** (25.0 mg, 0.035 mmol, 1 eq) was dissolved in anhydrous methanol saturated with gazeous hydrochloride (7.0 mL). After being stirred for 20 h at 60°C, the reaction mixture was concentrated to give a crude product which was immediately converted into the *N*-Boc derivative by treatment with di-tert butyl dicarbonate under standard conditions. Purification by preparative silica plate (3/2 EtOAc/Hep) afforded **19** as a white solid (18 mg, 88%): Rf = 0.25 (3/2 EtOAc/Hep); m.p. 82°C; $[\alpha]_D$ +34.0 (*c* 1.5, CHCl₃); IR (CHCl₃) v 3687, 3440, 3029, 3015, 2928, 2855, 2401, 1739, 1705, 1605, 1505, 1209, 1202, 1160 cm⁻¹; ¹H NMR (250 MHz, CDCl₃) δ 7.36 (dd, *J* = 1.8, 8.5 Hz, 1H), 7.08 (d, *J* = 1.8 Hz, 1H), 6.97 (d, *J* = 8.5 Hz, 1H), 6.51 (d, *J* = 2.0 Hz, 1H), 6.45 (d, *J* = 2.0 Hz, 1H), 5.60 (d, *J* = 8.9 Hz, 1H), 5.15 (d, *J* = 8.9 Hz, 1H), 4.82 (m, 1H), 3.98 (m, 2H), 3.84 (s, 3H), 3.77 (s, 3H), 3.70 (s, 3H), 3.59 (s, 3H), 1.45 (s, 9H), 1.41 (s, 9H); ¹³C NMR (62.5 MHz, CDCl₃) δ 172.1, 160.6, 157.6, 155.8, 154.8, 137.8, 124.8-130.8,

m/*z* 591; Anal. Calcd for $C_{30}H_{42}N_2O_{10}$: C, 61.00; H, 7.17; N, 4.74. Found: C, 60.38; H, 7.29; N, 4.34. HRMS (FAB) calcd for $[C_{30}H_{42}N_2O_{10}+H]^+$: 591.29177, found: 591.29398. CD (acetonitrile) $[\theta]_{260}$ -0.70, $[\theta]_{235}$ -3.65, $[\theta]_{225}$ 0, $[\theta]_{212}$ +10.00, $[\theta]_{201}$ 0.



Following the same protocole as described above, compound **18** was transformed into **20** with similar efficiency: Rf = 0.25 (3/2 EtOAc/Hep); m.p. 71°C; $[\alpha]_D$ +19.0 (*c* 1.5, CHCl₃); IR (CHCl₃) v 3685, 3618, 3349, 3026, 3015, 2977, 2400, 1747, 1706, 1604, 1506, 1424, 1228, 1205, 1045, 928 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.20 (dd, *J* = 2.0, 8.4 Hz, 1H), 7.11 (d, *J* = 2.0 Hz, 1H), 6.91 (d, *J* = 8.4 Hz, 1H), 6.52 (d, *J* = 2.0 Hz, 1H), 6.44 (d, *J* = 2.0 Hz, 1H), 5.38 (m, 1H), 5.19 (d, *J* = 7.3 Hz, 1H), 5.12 (d, *J* = 7.3 Hz, 1H), 4.77 (m, 1H), 3.60-3.80 (m, 2H), 3.82 (s, 3H), 3.70 (s, 3H), 3.67 (s, 3H), 3.66 (s, 3H), 1.41 (s, 9H), 1.33 (s, 9H); ¹³C NMR (62.5 MHz, CDCl₃) δ 172.1, 160.4, 158.9, 157.0, 155.8, 154.7, 136.8, 124.8-132.1, 120.3, 111.2, 103.8, 99.0, 80.1, 79.7, 66.2, 56.0, 55.8, 55.5, 55.3, 52.6, 28.4; MS (CI): *m/z* 591; Anal. Calcd for C₃₀H₄₂N₂O₁₀: C, 61.00; H, 7.17; N, 4.74. Found: C, 60.79; H, 7.24; N, 4.54. CD (acetonitrile) [θ]₂₆₀ +0.3, [θ]₂₂₈ +6.6, [θ]₂₁₉ 0, [θ]₂₀₄ -14.1, [θ]₁₉₈ 0.



A solution of alcohol **19** (17.0 mg, 0.028 mmol) in acetone (250.0 μ L) was cooled to 0°C. To this solution was added 21.6 μ L (0.056 mmol) of Jone's reagent (1 g of CrO₃ in 2.91 mL of H₂O and 0.84 mL of H₂SO₄). The reaction mixture was stirred under an argon atmosphere at -20°C for 15 h, quenched with H₂O and the aqueous phase was extracted with dichloromethane. The combined organic extracts were washed with brine, dried over Na₂SO₄, concentrated in vacuo to give the crude acid which was converted to the ester by treatment with a solution of CH₂N₂ in ether. Purification on a preparative silica plate (3/2 EtOAc/Hep) afforded desired compound **3** (14 mg, 80% global yield) and epimerized compound in a 7/1 ratio. Compound **3**: Rf = 0.36 (1/1)

EtOAc/Hep); [α]_D +20.5 (c 3.0, CHCl₃); IR (CHCl₃) v 3023, 2955, 2839, 2359, 1743, 1706, 1605, 1505, 1464, 1437, 1368, 1343, 1228, 1203, 1161, 1058 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.39 (br d, J = 8.4 Hz, 1H), 7.04 (br s, 1H), 6.95 (d, J = 8.4 Hz, 1H), 6.49 (br s, 1H), 6.46 (br s, 1H), 6.20 (d, J = 7.6 Hz, 1H), 5.48 (d, J = 9.0 Hz, 1H), 5.27 (d, J = 7.6 Hz, 1H), 5.17 (d, J = 7.6 Hz, 9.0 Hz, 1H), 3.84 (s, 3H), 3.76 (s, 3H), 3.68 (s, 3H), 3.66 (s, 3H), 3.59 (s, 3H), 1.45 (s, 9H), 1.44 (s, 9H); ¹³C NMR (62.5 MHz, CDCl₃) δ 172.4, 172.2, 160.0, 158.9, 158.3, 155.7, 154.9, 137.9, 127.9-131.8, 111.3, 119.8, 103.3, 98.4, 80.3, 79.9, 56.0, 55.9, 55.5, 54.8, 52.7, 52.4, 28.6; MS (EI): m/z 619; HRMS (FAB) calcd for $[C_{31}H_{42}N_2O_{11}+H]^+$: 619.28669, found: 619.28612. Epimer of compound **21:** Rf = 0.37 (1/1 EtOAc/Hep); $[\alpha]_D$ +23.0 (c 2.3, CHCl₃); IR (CHCl₃) v 3617, 3030, 3011, 2400, 2283, 1711, 1603, 1508, 1437, 1240, 1190 cm⁻¹; ¹H NMR $(300 \text{ MHz}, \text{CDCl}_3) \delta 8.10 \text{ (dd}, J = 2.0, 8.7 \text{ Hz}, 1\text{H}), 7.74 \text{ (d}, J = 2.0 \text{ Hz}, 1\text{H}), 7.03 \text{ (d}, J = 8.7 \text{ Hz})$ Hz, 1H), 6.56 (d, J = 2.3 Hz, 1H), 6.53 (d, J = 2.3 Hz, 1H), 5.30 (br s, 1H), 5.05 (d, J = 7 Hz, 1H), 3.88 (s, 3H), 3.86 (s, 6H), 3.67 (s, 3H), 3.59 (s, 3H), 1.40 (s, 9H), 1.32 (s, 9H); ¹³C NMR (62.5 MHz, CDCl₃) δ 171.2, 160.6, 158.9, 155.2, 155.0, 154.9, 137.2, 126.7-131.8, 119.2, 110.7, 104.2, 99.2, 80.5, 80.0, 56.0, 55.9, 55.6, 54.9, 52.7, 52.5, 28.6, 28.4; MS (ESI): 619, 641 [M+Na]⁺; HRMS (FAB) calcd for [C₃₁H₄₂N₂O₁₁+ H]⁺: 619.28669, found: 619.28619.



Following the same protocole as described above, compound **20** was transformed into **21** with similar efficiency. Partial epimerization was also observed. Compound **21**: Rf = 0.40 (1/1 EtOAc/Hep); $[\alpha]_D$ +10.0 (*c* 3.0, CHCl₃); IR (CHCl₃) v 3447, 2986, 2930, 2852, 2364, 1742, 1710, 1604, 1491, 1465, 1438, 1368, 1342, 1266, 1161 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.35 (dd, *J* = 2.0, 8.6 Hz, 1H), 7.15 (d, *J* = 2.0 Hz, 1H), 6.93 (d, *J* = 8.6 Hz, 1H), 6.51 (br s, 1H), 6.50 (br s, 1H), 5.50 (d, 1H), 5.30 (br s, 1H), 5.20 (br s, 1H), 4.92 (d, 1H), 3.83 (s, 3H), 3.73 (s, 3H), 3.70 (s, 3H), 3.67 (s, 3H), 3.62 (s, 3H), 1.45 (s, 9H), 1.41 (s, 9H); ¹³C NMR (50 MHz, CDCl₃) δ 172.1, 158.3, 160.6, 158.7, 154.7, 138.0, 128.4-131.2, 117.4, 111.1, 102.7, 99.1, 80.3, 79.9, 57.2, 56.0, 55.7, 55.6, 55.0, 52.6, 28.4; MS (EI): *m*/z 619; MS (ESI) 619, 641.2 [M+Na]⁺; HRMS (FAB) calcd for [C₃₁H₄₂N₂O₁₁+H]⁺: 619.28669, found: 619.28463. Epimer of **21**: Rf = 0.46 (1/1 EtOAc/Hep); [α]_D +24.0 (*c* 2.0, CHCl₃); IR (CHCl₃) v 3610, 3028, 3011, 2405, 2284, 1712, 1604, 1439, 1195 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 8.08 (dd, *J* = 8.6, 2.0Hz, 1H), 7.00 (d, *J* = 2.0 Hz, 1H), 6.00 (d, *J* = 8.6 Hz, 1H), 6.52 (d, *J* = 2.2 Hz, 1H), 6.40

(d, J = 2.2 Hz, 1H), 5.35 (bs, 1H), 5.15 (bs, 1H), 4.95 (bs, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.78 (s, 3H), 3.68 (s, 3H), 3.62 (s, 3H), 1.42 (s, 9H), 1.40 (s, 9H); ¹³C NMR (62.5 MHz, CDCl₃) δ 171.5, 160.8, 160.2, 158.4, 134.5, 122.7-131.6, 116.9, 110.4, 102.7, 99.0, 80.7, 79.9, 56.0, 55.9, 55.6, 55.0, 52.6, 51.9, 28.4; MS (EI): m/z 619; MS (ESI) 619, 641.2 [M+Na]⁺, 657.1 [M+K]⁺; HRMS (FAB) calcd for [C₃₁H₄₂N₂O₁₁]⁺: 618.27886, found: 618.28174.



To a solution of compound **19** (7 mg, 0.012 mmol) in methanol (250 µL) was added HCl at 0°C. The mixture was brought back to room temperature and stirred for 3 h. The reaction mixture was concentrated to give a crystalline solid, which was dissolved in anhydrous CH₂Cl₂ (400 µL) and cooled to -78°C, triphosgene (2.5 mg, 0.006 mmol) and triethylamine (4 µL, 0.024 mmol, 2 eq) were added. After being stirred at -78°C under an argon atmosphere for 6h, the reaction mixture was quenched with aqueous saturated NaHCO₃. The aqueous phase was extracted with CH₂Cl₂. The combined organic phase was washed with brine, dried over Na₂SO₄, concentrated. The crude product was purified on a preparative silica plate (3/2 EtOAc/Hep) to afford oxazolidinone **4** (4 mg, 80%) as a white opaque oil : Rf = 0.25 (3/2 EtOAc/Hep); $[\alpha]_D + 24.0$ (*c* 0.9, CHCl₃); IR (CHCl₃) v 3684, 3621, 3463, 3018, 2977, 2920, 2896, 2400, 2248, 1750, 1708, 1602, 1580, 1477, 1334, 1223, 1046, 929 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.65 (br s, 1H), 7.17 (br d, *J* = 8.2 Hz, 1H), 6.91 (d, *J* = 8.2 Hz, 1H), 6.69 (s, 1H), 6.53 (s, 1H), 6.11 (m, 2H), 4.88 (m, 1H), 4.67 (m, 2H), 4.22 (m, 1H), 3.85 (s, 3H), 3.78 (s, 3H), 3.72 (s, 3H), 3.63 (s, 3H); ¹³C NMR (62.5 MHz, CDCl₃) δ 167.8, 164.3, 162.3, 160.0, 152.0, 134.9, 125.9-129.4, 120.1, 111.2, 103.9, 100.1, 84.3, 60.4, 55.9, 55.7, 52.8; MS (CI): *m/z* 417.

(1) Davis, F. A.; Zhang, Y.; Andemichael, Y.; Fang, T.; Fanelli, D. L.; Zhang, H. J. Org. Chem. **1999**, *64*, 1403.